Biological factors influencing optimum fractionation in radiation therapy

Acta Oncologica

Volumn 40, Issue 6, 2001, Pages 712-717

  Fowler, J F ^a  

^a University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOSIMETRY; FRACTIONATION; TUMORS;

OPTIMUM SCHEDULES;

RADIOTHERAPY;

CANCER RADIOTHERAPY; CELL PROLIFERATION; CONFERENCE PAPER; DNA REPAIR; HEAD CANCER; HUMAN; LUNG NON SMALL CELL CANCER; NECK CANCER; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIATION DOSE;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; DNA DAMAGE; DNA REPAIR; DOSE FRACTIONATION; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; MODELS, THEORETICAL; PROSTATIC NEOPLASMS; RADIOTHERAPY;

EID: 0035183299     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860152619124     Document Type: Conference Paper

References (41)

1. The influence of number of fractions and of overall time on local control and late complications in squamous cell carcinoma of the larynx
2. Potential for increasing the differential response between tumors and normal tissues: Can proliferation rate be used
3. The hazard of accelerated clonogen repopulation during radiotherapy
4. Loss of local control with prolongation in radiotherapy
5. A modelled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy
6. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample
7. Studies with bromodeoxyuridine in head and neck cancer and accelerated radiotherapy
8. Relationship between potential doubling time (Tpot), labeling index and duration of DNA synthesis in 60 esophageal and 35 breast tumors: Is it worthwhile to measure Tpot
9. A comment on proliferation rates in human prostate cancer
10. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: Results of the EORTC 22851 randomised trial
11. Importance of overall treatment time in radiotherapy of the head and neck
12. Randomized clinical trial on accelerated 7 days per week fractionation in radiotherapy for head and neck cancer
13. A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer
14. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer
15. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: A randomised multicenter trial
16. Concomitant boost radiotherapy for advanced squamous cell carcinoma of the head and neck
17. Local control of oropharyngeal cancer after two accelerated hyperfractionation radiation therapy schemes
18. Improved results with accelerated hyperfractionated radiotherapy of advanced head and neck cancer
19. A radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003
20. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with non-small cell carcinoma of the lung: Analysis of 1 244 cases from 3 RTOG trials
21. Non-small cell lung tumors repopulate rapidly during radiation therapy
22. Confirmation of improved local-regional control with altered fractionation in head and neck cancer
23. How worthwhile are short schedules in radiotherapy? A series of exploratory calculations
24. The linear-quadratic formula and progress in fractionated radiotherapy
25. Estimation of tumor control probability parameters from 3-D dose distributions of non-small cell lung cancer patients
26. A new approach to dose escalation in non-small cell lung cancer
27. Accelerated repopulation during radiotherapy: Quantitative evidence for delayed onset
28. Time factors in larynx tumor radiotherapy: Lag times and intertumor heterogeneity in clinical data sets from four centers
29. A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma
30. Long-term results of accelerated radiation treatment for advanced head and neck cancer
31. Tomography
32. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: A final analysis of a randomized trial of the EORTC cooperative group of radiotherapy
33. Hyperfractionated radiotherapy of human tumors: Overview of the randomized clinical trials
34. Hyperfractionation: Where do we stand
35. A new incomplete-repair model based on a 'reciprocal-time' pattern of sublethal damage repair
36. Effect of time, dose and fractionation on temporal lobe necrosis following radiotherapy for nasopharyngeal carcinoma
37. The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: A multicenter analysis
38. Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: Dependency on tumor differentiation
39. Fractionation and protraction for radiotherapy of prostate carcinoma
40. Is α/β for prostate tumors really low?
41. Is the prostate α/β ratio of 1.5 from Brenner and Hall a modeling artefact